目的:调查可手术食管癌患者术前营养不足和营养风险发生率以及临床营养支持治疗的应用状况。方法:采用营养风险筛查2002(NRS2002)对住院手术治疗的202例食管癌患者进行营养风险调查,结合体质指数(body mass in-dex,BMI)判断营养风险和...目的:调查可手术食管癌患者术前营养不足和营养风险发生率以及临床营养支持治疗的应用状况。方法:采用营养风险筛查2002(NRS2002)对住院手术治疗的202例食管癌患者进行营养风险调查,结合体质指数(body mass in-dex,BMI)判断营养风险和营养不足发生率;同时调查患者住院期间营养支持治疗的应用状况。结果:所有患者中,BMI<18.5kg/m2者54例,营养不足发生率为26.7%(54/202);NRS2002评分≥3分者116例,营养风险发生率为57.4%(116/202);年龄是否>65岁(χ2值分别为6.233、4.730)、术后分期(χ2值分别为7.214、7.191)、梗阻程度(χ2值分别为41.507、51.447)、文化程度(χ2值分别为5.158、10.260)是发生营养不良和营养风险的影响因素,P<0.05。城乡差异和工作性质只与营养不足发生率有关,χ2值分别为6.537、9.197,P值分别为0.011、0.010;而与营养风险发生率无关,χ2值分别为0.300、3.668,P值分别为0.584、0.160;营养不足和营养风险与食管癌发生的部位无关,χ2值分别为2.859、4.551,P值分别为0.239、0.103。经Logistic回归分析后发现,术后分期、梗阻程度和文化程度是营养不足和营养风险发生的影响因素。全部患者中,应用了营养支持治疗者137例(72.3%),其中采用肠内营养支持治疗(enteral nutrition,EN)者48例(35.0%),肠外营养支持治疗(parenteral nutrition,PN)者89例(65.0%),EN/PN为1/1.85;EN在术后28～72h,平均为术后56h;在NRS2002评分≥3分的116例患者中,给予营养支持治疗98例(84.5%),而在NRS2002评分<3分的86例患者中,也有39例(45.3%)给予了营养支持治疗。结论:食管癌手术患者营养不足和营养风险发生率较高,营养支持治疗在临床应用中还存在一定的不合理性。展开更多
目的:探讨肠内营养辅助治疗对食管癌患者术后吻合口瘘的预防效果及对患者免疫功能、愈合进程及营养恢复的影响。方法:回顾性分析90例行手术治疗的食管癌患者临床资料,根据其术后营养辅助治疗方式分为A(n=34)、B(n=30)、C(n=26)三组。A...目的:探讨肠内营养辅助治疗对食管癌患者术后吻合口瘘的预防效果及对患者免疫功能、愈合进程及营养恢复的影响。方法:回顾性分析90例行手术治疗的食管癌患者临床资料,根据其术后营养辅助治疗方式分为A(n=34)、B(n=30)、C(n=26)三组。A组接受免疫增强型肠内营养(瑞能)辅助治疗方案,B组采用常规肠内营养(能全力)辅助治疗方案,两组均于术后第1天、第2天及第3~7天给予全量的25%、50%和100%后,逐日减少剂量直至过渡到正常饮食;C组接受肠外营养辅助治疗方案,术后第1天起静脉输注葡萄糖、维生素、氨基酸等混合液,以125.52 k J/kg计算,应用8~10 d后逐渐过渡至正常饮食。观察对比三组受试者术后吻合口瘘、肺部感染、切口感染发生率及创口愈合时间、总住院时间、首次排气时间差异,记录其术前及术后第1、8天时免疫指标[T淋巴细胞及其亚群(CD3^+、CD4^+、CD8^+)]、炎症因子[C反应蛋白(CRP)、IL-6]、营养指标[血清总蛋白(TP)、清蛋白(ALB)]变化情况。结果:(1)三组术后吻合口瘘及肺部感染发生率对比差异有统计学意义(P<0.05),且C组发生率显著高于其他两组(P<0.05)。(2)三组创口愈合时间、总住院时间及首次排气时间对比均有统计学意义(P<0.05),且C组均长于其他两组(P<0.05)。(3)术后第1天,三组患者CD3^+、CD4^+、CD4^+/CD8^+等免疫指标水平及TP、ALB等营养指标水平均较术前显著降低,CD8^+水平及CRP、IL-6等炎症因子水平则较术前显著提升(P<0.05),但组间对比无统计学意义(P>0.05)。术后第8天,三组各营养指标仍明显低于术前,但A、B组显著高于C组(P<0.05);各炎症因子指标仍显著高于术前(P<0.05),但A、B组显著低于C组(P<0.05)。三组中A组术后第8天各免疫指标与术前比较无统计学意义(P>0.05),其余两组患者CD3^+、CD4^+、CD4^+/CD8^+水平均较术前降低,CD8^+水平则明显提升(P<0.05)。结论:食管癌患者术后�展开更多
AIM: To investigate the role of perioperative chemoradiotherapy (CRT) in the treatment of locally advanced thoracic esophageal squamous cell carcinoma (ESCC). METHODS: Using preoperative computed tomography (CT)-based...AIM: To investigate the role of perioperative chemoradiotherapy (CRT) in the treatment of locally advanced thoracic esophageal squamous cell carcinoma (ESCC). METHODS: Using preoperative computed tomography (CT)-based staging criteria, 238 patients with ESCC (stage ⅡⅢ ) were enrolled in this prospective study between January 1997 and June 2004. With informed consent, patients were randomized into 3 groups: preoperative CRT (80 cases), postoperative CRT (78 cases) and surgery alone (S) (80 cases). The 1-, 3-, 5and 10-year survival were followed up. Progressionfree survival (PFS) was chosen as the primary endpoint by treatment arm measured from study entry until documented progression of disease or death from any cause. The secondary endpoint was overall survival (OS) determined as the time (in months) between the date of therapy and the date of death. Other objectives were surgical and adjuvant therapy complications.RESULTS: With median follow-up of 45 mo for all the enrolled patients, significant differences in the 1-, 3-, 5-, 10-year OS (91.3%, 63.5%, 43.5%, 24.5% vs 91%, 62.8%, 42.3%, 24.4% vs 87.5%, 51.3%, 33.8%, 12.5%, P = 0.0176) and PFS (89.3%, 61.3%, 37.5%, 18.1% vs 89.1%, 61.1%, 37.2%, 17.8% vs 84.5%, 49.3%, 25.9%, 6.2%, P = 0.0151) were detected among the 3 arms. There were no significant differences in OS and PFS between the preoperative CRT and postoperative CRT arm (P > 0.05). For the patients who had radical resection, significant differences in median PFS (48 mo vs 61 mo vs 39.5 mo, P = 0.0331) and median OS (56.5 mo vs 72 mo vs 41.5 mo, P = 0.0153) were detected among the 3 arms, but there were no significant differences in OS and PFS between the preoperative CRT and postoperative CRT arm (P > 0.05). The local recurrence rates in the preoperative CRT, postoperative CRT group and S group were 11.3%, 14.1% and 35%, respectively (P < 0.05). No significant differences were detected among the 3 groups when comparing complications but tended to be in favor of the postoperative CRT and S groups (P > 0展开更多
文摘目的:调查可手术食管癌患者术前营养不足和营养风险发生率以及临床营养支持治疗的应用状况。方法:采用营养风险筛查2002(NRS2002)对住院手术治疗的202例食管癌患者进行营养风险调查,结合体质指数(body mass in-dex,BMI)判断营养风险和营养不足发生率;同时调查患者住院期间营养支持治疗的应用状况。结果:所有患者中,BMI<18.5kg/m2者54例,营养不足发生率为26.7%(54/202);NRS2002评分≥3分者116例,营养风险发生率为57.4%(116/202);年龄是否>65岁(χ2值分别为6.233、4.730)、术后分期(χ2值分别为7.214、7.191)、梗阻程度(χ2值分别为41.507、51.447)、文化程度(χ2值分别为5.158、10.260)是发生营养不良和营养风险的影响因素,P<0.05。城乡差异和工作性质只与营养不足发生率有关,χ2值分别为6.537、9.197,P值分别为0.011、0.010;而与营养风险发生率无关,χ2值分别为0.300、3.668,P值分别为0.584、0.160;营养不足和营养风险与食管癌发生的部位无关,χ2值分别为2.859、4.551,P值分别为0.239、0.103。经Logistic回归分析后发现,术后分期、梗阻程度和文化程度是营养不足和营养风险发生的影响因素。全部患者中,应用了营养支持治疗者137例(72.3%),其中采用肠内营养支持治疗(enteral nutrition,EN)者48例(35.0%),肠外营养支持治疗(parenteral nutrition,PN)者89例(65.0%),EN/PN为1/1.85;EN在术后28～72h,平均为术后56h;在NRS2002评分≥3分的116例患者中,给予营养支持治疗98例(84.5%),而在NRS2002评分<3分的86例患者中,也有39例(45.3%)给予了营养支持治疗。结论:食管癌手术患者营养不足和营养风险发生率较高,营养支持治疗在临床应用中还存在一定的不合理性。
文摘目的:探讨肠内营养辅助治疗对食管癌患者术后吻合口瘘的预防效果及对患者免疫功能、愈合进程及营养恢复的影响。方法:回顾性分析90例行手术治疗的食管癌患者临床资料,根据其术后营养辅助治疗方式分为A(n=34)、B(n=30)、C(n=26)三组。A组接受免疫增强型肠内营养(瑞能)辅助治疗方案,B组采用常规肠内营养(能全力)辅助治疗方案,两组均于术后第1天、第2天及第3~7天给予全量的25%、50%和100%后,逐日减少剂量直至过渡到正常饮食;C组接受肠外营养辅助治疗方案,术后第1天起静脉输注葡萄糖、维生素、氨基酸等混合液,以125.52 k J/kg计算,应用8~10 d后逐渐过渡至正常饮食。观察对比三组受试者术后吻合口瘘、肺部感染、切口感染发生率及创口愈合时间、总住院时间、首次排气时间差异,记录其术前及术后第1、8天时免疫指标[T淋巴细胞及其亚群(CD3^+、CD4^+、CD8^+)]、炎症因子[C反应蛋白(CRP)、IL-6]、营养指标[血清总蛋白(TP)、清蛋白(ALB)]变化情况。结果:(1)三组术后吻合口瘘及肺部感染发生率对比差异有统计学意义(P<0.05),且C组发生率显著高于其他两组(P<0.05)。(2)三组创口愈合时间、总住院时间及首次排气时间对比均有统计学意义(P<0.05),且C组均长于其他两组(P<0.05)。(3)术后第1天,三组患者CD3^+、CD4^+、CD4^+/CD8^+等免疫指标水平及TP、ALB等营养指标水平均较术前显著降低,CD8^+水平及CRP、IL-6等炎症因子水平则较术前显著提升(P<0.05),但组间对比无统计学意义(P>0.05)。术后第8天,三组各营养指标仍明显低于术前,但A、B组显著高于C组(P<0.05);各炎症因子指标仍显著高于术前(P<0.05),但A、B组显著低于C组(P<0.05)。三组中A组术后第8天各免疫指标与术前比较无统计学意义(P>0.05),其余两组患者CD3^+、CD4^+、CD4^+/CD8^+水平均较术前降低,CD8^+水平则明显提升(P<0.05)。结论:食管癌患者术后�
文摘AIM: To investigate the role of perioperative chemoradiotherapy (CRT) in the treatment of locally advanced thoracic esophageal squamous cell carcinoma (ESCC). METHODS: Using preoperative computed tomography (CT)-based staging criteria, 238 patients with ESCC (stage ⅡⅢ ) were enrolled in this prospective study between January 1997 and June 2004. With informed consent, patients were randomized into 3 groups: preoperative CRT (80 cases), postoperative CRT (78 cases) and surgery alone (S) (80 cases). The 1-, 3-, 5and 10-year survival were followed up. Progressionfree survival (PFS) was chosen as the primary endpoint by treatment arm measured from study entry until documented progression of disease or death from any cause. The secondary endpoint was overall survival (OS) determined as the time (in months) between the date of therapy and the date of death. Other objectives were surgical and adjuvant therapy complications.RESULTS: With median follow-up of 45 mo for all the enrolled patients, significant differences in the 1-, 3-, 5-, 10-year OS (91.3%, 63.5%, 43.5%, 24.5% vs 91%, 62.8%, 42.3%, 24.4% vs 87.5%, 51.3%, 33.8%, 12.5%, P = 0.0176) and PFS (89.3%, 61.3%, 37.5%, 18.1% vs 89.1%, 61.1%, 37.2%, 17.8% vs 84.5%, 49.3%, 25.9%, 6.2%, P = 0.0151) were detected among the 3 arms. There were no significant differences in OS and PFS between the preoperative CRT and postoperative CRT arm (P > 0.05). For the patients who had radical resection, significant differences in median PFS (48 mo vs 61 mo vs 39.5 mo, P = 0.0331) and median OS (56.5 mo vs 72 mo vs 41.5 mo, P = 0.0153) were detected among the 3 arms, but there were no significant differences in OS and PFS between the preoperative CRT and postoperative CRT arm (P > 0.05). The local recurrence rates in the preoperative CRT, postoperative CRT group and S group were 11.3%, 14.1% and 35%, respectively (P < 0.05). No significant differences were detected among the 3 groups when comparing complications but tended to be in favor of the postoperative CRT and S groups (P > 0
